{"version":"1.0","type":"link","title":"A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.","author_name":"Akhavan B 외","author_url":"https://prs-insight.online/author/Akhavan%20B","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/168752","thumbnail_width":1200,"thumbnail_height":630}